316 related articles for article (PubMed ID: 11673692)
21. [Epidermal growth factor receptors (EGFR): a new target for anticancer therapy].
Gainet M; Guardiola E; Dufresne A; Pivot X
Cancer Radiother; 2003 Jun; 7(3):195-9. PubMed ID: 12834777
[TBL] [Abstract][Full Text] [Related]
22. Why the epidermal growth factor receptor? The rationale for cancer therapy.
Baselga J
Oncologist; 2002; 7 Suppl 4():2-8. PubMed ID: 12202782
[TBL] [Abstract][Full Text] [Related]
23. Targeting the epidermal growth factor receptor.
El-Rayes BF; LoRusso PM
Br J Cancer; 2004 Aug; 91(3):418-24. PubMed ID: 15238978
[TBL] [Abstract][Full Text] [Related]
24. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme.
Eller JL; Longo SL; Hicklin DJ; Canute GW
Neurosurgery; 2002 Oct; 51(4):1005-13; discussion 1013-4. PubMed ID: 12234411
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor inhibition strategies in oncology.
Harari PM
Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
[TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
Yewale C; Baradia D; Vhora I; Patil S; Misra A
Biomaterials; 2013 Nov; 34(34):8690-707. PubMed ID: 23953842
[TBL] [Abstract][Full Text] [Related]
27. Role of an anti-epidermal growth factor receptor in treating cancer.
Waksal HW
Cancer Metastasis Rev; 1999; 18(4):427-36. PubMed ID: 10855786
[TBL] [Abstract][Full Text] [Related]
28. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family.
Bellmunt J; Hussain M; Dinney CP
Crit Rev Oncol Hematol; 2003 Jun; 46 Suppl():S85-104. PubMed ID: 12850530
[TBL] [Abstract][Full Text] [Related]
29. Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations.
Perez-Torres M; Guix M; Gonzalez A; Arteaga CL
J Biol Chem; 2006 Dec; 281(52):40183-92. PubMed ID: 17082181
[TBL] [Abstract][Full Text] [Related]
30. Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.
Ciardiello F; De Vita F; Orditura M; De Placido S; Tortora G
Expert Opin Emerg Drugs; 2003 Nov; 8(2):501-14. PubMed ID: 14662002
[TBL] [Abstract][Full Text] [Related]
31. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.
Brand TM; Iida M; Wheeler DL
Cancer Biol Ther; 2011 May; 11(9):777-92. PubMed ID: 21293176
[TBL] [Abstract][Full Text] [Related]
32. Epithelial growth factor receptor interacting agents.
Baselga J; Albanell J
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1041-63. PubMed ID: 12512382
[TBL] [Abstract][Full Text] [Related]
33. Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide.
Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; Pepe S; Bianco AR; Agrawal S; Mendelsohn J; Tortora G
J Natl Cancer Inst; 1998 Jul; 90(14):1087-94. PubMed ID: 9672257
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological background of EGFR targeting.
Castillo L; Etienne-Grimaldi MC; Fischel JL; Formento P; Magné N; Milano G
Ann Oncol; 2004 Jul; 15(7):1007-12. PubMed ID: 15205192
[TBL] [Abstract][Full Text] [Related]
35. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
36. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents.
Ciardiello F
Drugs; 2000; 60 Suppl 1():25-32; discussion 41-2. PubMed ID: 11129169
[TBL] [Abstract][Full Text] [Related]
37. Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives.
Zhu Z
Acta Pharmacol Sin; 2007 Sep; 28(9):1476-93. PubMed ID: 17723181
[TBL] [Abstract][Full Text] [Related]
38. Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC-C225.
Hollywood E
Semin Oncol Nurs; 2002 May; 18(2 Suppl 2):30-5. PubMed ID: 12053862
[TBL] [Abstract][Full Text] [Related]
39. Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer.
Gridelli C; Maione P; Ferrara ML; Rossi A
Oncologist; 2009 Jun; 14(6):601-11. PubMed ID: 19482958
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice.
Overholser JP; Prewett MC; Hooper AT; Waksal HW; Hicklin DJ
Cancer; 2000 Jul; 89(1):74-82. PubMed ID: 10897003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
